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Background. Oral anticoagulation is the mainstay of
stroke prevention in atrial fibrillation (AF), but
must be balanced against the associated bleeding
risk. Several risk scores have been proposed for
prediction of bleeding events in patients with AF.
Objectives. To compare the performance of contem-
porary clinical bleeding risk scores in 18 113
patients with AF randomized to dabigatran
110 mg, 150 mg or warfarin in the RE-LY trial.
Methods. HAS-BLED, ORBIT, ATRIA and HEMOR-
R2HAGES bleeding risk scores were calculated
based on clinical information at baseline. All major
bleeding events were centrally adjudicated.
Results. There were 1182 (6.5%) major bleeding
events during a median follow-up of 2.0 years.
For all the four schemes, high-risk subgroups had
higher risk of major bleeding (all P < 0.001). The
ORBIT score showed the best discrimination with
c-indices of 0.66, 0.66 and 0.62, respectively, for
major, life-threatening and intracranial bleeding,
which were significantly better than for the HAS-
BLED score (difference in c-indices: 0.050, 0.053
and 0.048, respectively, all P < 0.05). The ORBIT
score also showed the best calibration compared
with previous data. Significant treatment interac-
tions between the bleeding scores and the risk of
major bleeding with dabigatran 150 mg BD versus
warfarin were found for the ORBIT (P = 0.0019),
ATRIA (P < 0.001) and HEMORR2HAGES
(P < 0.001) scores. HAS-BLED score showed a
nonsignificant trend for interaction (P = 0.0607).
Conclusions. Amongst the current clinical bleeding risk
scores, the ORBIT score demonstrated the best dis-
crimination and calibration. All the scores demon-
strated, to a variable extent, an interaction with
bleeding risk associated with dabigatran or warfarin.
Keywords: anticoagulation treatment, atrial fibrillation,
bleeding risk scores, dabigatran, major bleeding.
Introduction
Atrial fibrillation (AF) is associated with a signif-
icant increase in risk for stroke and thromboem-
bolic events which is variable between different
patients [1–3]. Treatment with oral anticoagulant
(OAC) is the cornerstone in prevention of
thromboembolic events in AF patients at an
increased risk of stroke [1]. However, OAC
treatment is unavoidably associated with an
increased risk of bleeding, regardless of OAC
type used [4, 5].
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Nonvitamin K antagonist oral anticoagulants
(NOACs) have been shown to be safer than warfarin
in relation to major bleeding events, particularly
intracranial haemorrhage [6]. All of the NOACs are
now recommended in all guidelines [1–3, 7, 8] for
stroke prevention in AF and in some guidelines in
preference to vitamin K antagonist for the majority
of AF patients [1, 3, 8].
Baseline evaluation of bleeding risk is mandatory
[1–3, 7, 8] during the decision-making process of
prescribing OAC therapy, as well as throughout
follow-up, as bleeding risk may change over time.
In recent years, several clinical prediction scores
have been developed and validated in large cohorts
and can be used as tools for bleeding risk evalu-
ation in AF patients, namely ‘Hypertension, Abnor-
mal liver/renal function, Stroke, Bleeding, Labile
International Normalized Ratio, Elderly, Drugs or
alcohol’ (HAS-BLED) [9], ‘Older age, Reduced
haemoglobin/haematocrit/anaemia, Bleeding his-
tory, Insufficient kidney function, Treatment with
platelets’ (ORBIT) [10], ‘Anticoagulation and Risk
Factors in Atrial Fibrillation’ (ATRIA) Bleeding [11],
‘Hepatic or renal disease, Ethanol abuse, Malig-
nancy history, Older (age > 75), Reduced platelet
count or function, Rebleeding risk, Hypertension,
Anaemia, Genetic factors, Excessive fall risk,
Stroke history’ (HEMORR2HAGES) [12] and ‘Age,
Biomarkers, Clinical history’ (ABC)-bleeding [13]
scores. Currently, most of the international guide-
lines propose the use of clinical tools to assess
bleeding risk [1, 3, 7]. So far there are few studies
which have focused on comparisons and validation
of the different bleeding scores in patients treated
with NOACs [10, 14, 15].
The aims of the current analyses are twofold: (i) to
compare the predictive performance of HAS-BLED,
ORBIT, ATRIA and HEMORR2HAGES bleeding
scores in patients with AF enrolled in the ‘Ran-
domized Evaluation of Long-term anticoagulant
therapY’ (RE-LY) Trial; and (ii) to evaluate the
interaction between predicted high risk of bleeding,
according to the bleeding risk scores, and the
effects on major bleeding by treatment with dabi-
gatran (either 110 mg and 150 mg BID) or war-
farin.
Methods
Details about the study design and main results
have been reported elsewhere [16, 17]. Briefly, the
RE-LY trial enrolled 18 113 patients with
nonvalvular AF who were randomized to receive
OAC therapy with dabigatran 110 mg BID, dabi-
gatran 150 mg BID or dose-adjusted warfarin
(international normalized ratio (INR) target 2.0–
3.0). The median duration of follow-up was
2.0 years. The study was conducted according to
Good Clinical Practice recommendations and the
Declaration of Helsinki. All enrolled patients were
considered for this post hoc analysis of the RE-LY
trial.
The HAS-BLED, ORBIT, ATRIA and HEMOR-
R2HAGES scores were computed according to
original definitions [9–12]. Details about the com-
ponents, definitions and risk categories for the
evaluated bleeding risk prediction scores are avail-
able in the web-only Supplementary Methods.
The primary outcome for this analysis was the
occurrence of major bleeding, the primary safety
end-point in the RE-LY trial, defined according to
the original study protocol as a reduction in the
haemoglobin level of at least 20 g L1, transfusion
of at least 2 units of blood or symptomatic bleeding
in a critical area or organ [17]. Life-threatening
bleeding and intracranial bleeding were considered
as secondary outcomes. Life-threatening bleeding
was a subcategory of major bleeding that consisted
of fatal bleeding, symptomatic intracranial bleed-
ing, bleeding with a decrease in the haemoglobin
level of at least 50 g L1, or bleeding requiring
transfusion of at least 4 units of blood or inotropic
agents or necessitating surgery [17]. All bleeding
events were centrally adjudicated by an indepen-
dent clinical events committee blinded to treatment
assignment. The current analyses have been per-
formed incorporating the additional events
reported and adjudicated after the release of the
study main results [18].
Statistical analysis
Categorical variables have been reported as counts
and percentages, whilst continuous variables have
been reported as median and interquartile range.
Comparisons between categorical variables have
been performed with chi-squared test, whilst com-
parisons between continuous variables were per-
formed according to the Wilcoxon rank sum test.
Outcomes are expressed as annualized incidence
rates.
The discriminative ability of the scores was
assessed and compared using Harrell’s C-index.
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Confidence interval for differences between C-
indexes was obtained using 1000 bootstrap sam-
ples. Calibration was evaluated by plots of major
bleeding events rates per 100 patient-years (95%
confidence interval) observed in the RE-LY trial vs.
the previously published event rates from the
original derivation cohorts. Interactions between
study treatments and risk scores (in clinically
meaningful risk categories as well as in continuous
form) regarding study outcomes were evaluated by
Cox proportional hazards models. As reported in
the Supplementary Methods, a sensitivity analysis
for HAS-BLED with alternative definition of ‘Labile
INR’ criterion was performed. A 2-sided P < 0.05
was considered statistically significant, and as all
analyses were exploratory, there were no adjust-
ments for multiple comparisons. All analyses were
performed with SAS software, version 9.4 (SAS
Institute Inc., Cary, NC, USA).
Results
A total of 1182 (6.5%) major bleeding events
occurred and were adjudicated, with an overall
annual rate of 3.31% per year. Amongst these
events, 47.0% (n = 555) were life-threatening
bleeding events with an overall annual rate of
1.55% per year. Intracranial bleeds occurred in
157 (13.3% of major bleeding events), with an
overall annual rate of 0.44% per year events.
Clinical characteristics of patients according to
major bleeding occurrence are summarized in
Table 1.
As previously reported elsewhere, patients report-
ing a major bleeding occurrence were more likely to
be older, hypertensive and with a previous history
of stroke/transient ischemic attack/systemic
embolic event [17, 19]. Patients who experienced
major bleeding had a higher thromboembolic risk
(P < 0.0001) (Table 1). Results were similar when
separately analysed by randomized treatment
(Table S1).
Risk score distribution and bleeding outcomes
HAS-BLED, ORBIT, ATRIA and HEMORR2HAGES
median scores were higher (all P < 0.0001) in
patients that experienced major bleeding com-
pared to those patients who did not (Table 2).
Accordingly, the proportion of patients assigned to
the high-risk category was consistently higher for
those that reported major bleeding during follow-
up for all four bleeding risk scores (all
P < 0.0001).
Analysing the bleeding risk scores distribution in
relation to the randomized treatment yielded sim-
ilar results with higher values for the bleeding risk
scores in patients that experienced major bleeding
(Table S2). Similarly, the proportion allotted to
high-risk categories within each score was higher
amongst the patients that reported a major bleed-
ing occurrence for all the randomized treatments
(Table S2).
Discriminative performance
Predictive performances of the bleeding risk scores
are reported in Table 3. All bleeding risk scores
showed a significant, albeit, modest predictive
capacity. Amongst the overall cohort, the best
discrimination in predicting major bleeding occur-
rence was shown using the ORBIT score (c-index:
0.66). Stratifying the results according to the
randomized treatment, all the bleeding risk scores
demonstrated significant predictive ability for all
randomized treatment groups (Table 3). The ORBIT
score also demonstrated the best discriminative
ability across randomized OAC treatment groups
(c-indexes: 0.68, 0.70 and 0.62, for dabigatran
110 mg, dabigatran 150 mg and warfarin, respec-
tively). Similar results were obtained for life-
threatening bleeding occurrence. For the intracra-
nial bleeding outcome, all the scores had lower
predictive ability, both in the overall population
and in the randomized treatments subgroups
(Table 3). The ORBIT score was consistently the
best predictor for intracranial bleeding amongst
the three treatment subgroups, whilst the predic-
tive ability of the HAS-BLED, ATRIA and HEMOR-
R2HAGES was found to be broadly nonsignificant
amongst patients randomized to both dabigatran
110 mg and dabigatran 150 mg.
When comparing the discriminative abilities of the
four bleeding scores (Table 4), the ORBIT score was
consistently found to be significantly better than
HAS-BLED, across the three bleeding outcomes
(differences in c-indices: 0.050, 0.053 and 0.048,
for major bleeding, life-threatening bleeding and
intracranial bleeding, respectively). The ATRIA
score performed better than HAS-BLED only for
prediction of major bleeding, whilst differences in
the c-indexes for the other outcomes were non-
significant. HEMORR2HAGES performed similarly
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to HAS-BLED for all the outcomes considered
(Table 4).
Calibration analysis
Evaluation of calibration, the comparison between
estimated and actually observed event rates, for
the four bleeding scores demonstrated that the
ORBIT score had the best agreement over the range
of bleeding risk when compared to the original
derivation cohort (Fig. 1). Conversely, the ATRIA
score showed the largest mismatch in calibration.
The ATRIA and HAS-BLED scores, to different
degrees, tended to overestimate the risk of bleed-
ing. The HEMORR2HAGES score underestimated
the risk of bleeding events, in particularly for those
patients with a higher predicted risk (Fig. 1).
Treatment effect interactions with bleeding risk scores
Major bleeding incidence rates progressively
increased according to increasing scores for all
Table 1 Baseline characteristics according major bleeding occurrence
Major bleeding
P-value
Yes
N = 1182
No
N = 16 931
Age, (years) median [IQR] 76 [71–80] 72.0 [66–77] <0.0001
Age ≥75 years, n (%) 670 (56.7) 6568 (38.8) <0.0001
Female, n (%) 413 (34.9) 6185 (36.5) 0.27
SBP, (mmHg) median [IQR] (18 086)* 130 [118–140] 130 [120–140] 0.0046
CrCL (mL min1), median [IQR] (17 375)* 59.9 [46.9–75.7] 69.1 [53.9–87.4] <0.0001
Hypertension, n (%) 970 (82.1) 13 313 (78.6) 0.0053
Diabetes Mellitus, n (%) 354 (29.9) 3867 (22.8) <0.0001
CAD, n (%) 449 (38.0) 4585 (27.1) <0.0001
Previous Stroke/SEE/TIA, n (%) 289 (24.5) 3664 (21.6) 0.0238
Symptomatic HF (NYHA ≥ 2), n (%) 325 (27.5) 4579 (27.1) 0.73
CrCL Category, n (%) (17 375)*
<50 mL min1 360 (31.4) 3060 (18.9) <0.0001
50–79 mL min1 554 (48.3) 7743 (47.7)
≥80 mL min 1 234 (20.4) 5424 (33.4)
History of Fall, n (%) 205 (17.4) 1842 (10.9) <0.0001
Anaemia, n (%) 327 (27.7) 2146 (12.7) <0.0001
Malignancy, n (%) 171 (14.5) 1714 (10.1) <0.0001
Previous VKA Use, n (%)
Experienced 603 (51.0) 8381 (49.5) 0.32
Naive 579 (49.0) 8547 (50.5)
Concomitant ASA, n (%) 556 (47.0) 6597 (39.0) <0.0001
Statins, n (%) 576 (48.7) 7481 (44.2) 0.0024
H2 Blockers, n (%) 65 (5.5) 693 (4.1) 0.0196
ACEi/ARB, n (%) 805 (68.1) 11 178 (66.0) 0.14
Amiodarone, n (%) 113 (9.6) 1863 (11.0) 0.12
PPI, n (%) 225 (19.0) 2342 (13.8) <0.0001
CHADS2, median [IQR] 2 [2,3] 2 [1–3] <0.0001
*Total number of patients with available data about the covariate; ACEi, angiotensin converting enzyme inhibitor; ARBs,
angiotensin receptor blocker; ASA, acetylsalicylic acid; CAD, coronary artery disease; CrCl, creatinine clearance; HF, heart
failure; IQR, interquartile range; PPI, proton pump inhibitor; SBP, systolic blood pressure; SEE, systemic embolic event;
TIA, transient ischemic attack; VKA, vitamin K antagonist.
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Table 2 Bleeding risk score categories according to major bleeding occurrence
Overall
N = 18 113
Major bleeding
P-value
No
N = 16 931
Yes
N = 1182
HAS-BLED, median [IQR] 2 [1–2] 2 [1–2] 2 [1–3] <0.0001
HAS-BLED categories, n (%)
Low (0–2) 14 684 (81.1) 13 874 (81.8) 810 (69.7) <0.0001
High (>2) 3429 (18.9) 3077 (18.2) 352 (30.3)
ORBIT, median [IQR] 1 [1–2] 1 [1–2] 2 [1–3] <0.0001
ORBIT categories, n (%)
Low (0–2) 14 203 (78.4) 13 517 (79.7) 686 (59.0) <0.0001
Intermediate (3) 2371 (13.1) 2144 (12.6) 227 (19.5)
High (>3) 1539 (8.5) 1290 (7.6) 249 (21.4)
ATRIA, median [IQR] 0 [0–2] 0 [0–2] 2 [0–3] <0.0001
ATRIA categories, n (%)
Low (0–4) 16 746 (92.5) 15 787 (93.1) 959 (82.5) <0.0001
Intermediate/High (≥4) 1367 (7.5) 1164 (6.9) 203 (17.5)
HEMORR2HAGES, median [IQR] 1 [0–2] 1 [0–2] 1 [1–2] <0.0001
HEMORR2HAGES categories, n (%)
Low (0–1) 12 874 (71.1) 12 239 (72.2) 635 (54.6) <0.0001
Intermediate (2–3) 4932 (27.2) 4449 (26.2) 483 (41.6)
High (>3) 307 (1.7) 263 (1.6) 44 (3.8)
ATRIA, Anticoagulation and Risk Factors in Atrial Fibrillation; HAS-BLED, Hypertension, Abnormal liver/renal function,
Stroke, Bleeding, Labile International Normalized Ratio, Elderly, Drugs or alcohol; HEMORR2HAGES, Hepatic or renal
disease, Ethanol abuse, Malignancy history, Older (age > 75), Reduced platelet count or function, Rebleeding risk,
Hypertension, Anaemia, Genetic factors, Excessive fall risk, Stroke history; IQR, interquartile range; ORBIT, Older age,
Reduced haemoglobin/haematocrit/anaemia, Bleeding history, Insufficient kidney function, Treatment with platelets.
Table 3 Discriminative abilities for the bleeding risk scores according to randomized treatment and outcomes occurrences
Outcome Risk Score*
C-index (95% CI)
Overall Dabigatran 110 Dabigatran 150 Warfarin
Major bleeding HAS-BLED 0.62 (0.60–0.63) 0.61 (0.58–0.64) 0.64 (0.62–0.67) 0.59 (0.57–0.62)
ORBIT 0.66 (0.65–0.68) 0.68 (0.65–0.71) 0.70 (0.68–0.73) 0.62 (0.59–0.64)
ATRIA 0.64 (0.62–0.65) 0.64 (0.61–0.67) 0.67 (0.65–0.70) 0.59 (0.57–0.62)
HEMORR2HAGES 0.62 (0.61–0.64) 0.61 (0.58–0.64) 0.66 (0.64–0.69) 0.59 (0.56–0.62)
Life-threatening bleeding HAS-BLED 0.61 (0.59–0.64) 0.60 (0.56–0.64) 0.65 (0.61–0.69) 0.59 (0.55–0.63)
ORBIT 0.66 (0.64–0.68) 0.67 (0.63–0.71) 0.71 (0.68–0.75) 0.62 (0.58–0.65)
ATRIA 0.63 (0.61–0.66) 0.63 (0.58–0.67) 0.68 (0.64–0.72) 0.59 (0.56–0.63)
HEMORR2HAGES 0.62 (0.60–0.64) 0.61 (0.57–0.66) 0.66 (0.63–0.70) 0.59 (0.56–0.62)
Intracranial bleeding HAS-BLED 0.56 (0.52–0.61) 0.52 (0.42–0.63) 0.56 (0.48–0.64) 0.57 (0.52–0.63)
ORBIT 0.62 (0.57–0.66) 0.63 (0.55–0.72) 0.60 (0.50–0.69) 0.62 (0.57–0.67)
ATRIA 0.58 (0.54–0.63) 0.59 (0.50–0.69) 0.59 (0.50–0.68) 0.58 (0.52–0.63)
HEMORR2HAGES 0.59 (0.55–0.64) 0.54 (0.44–0.65) 0.61 (0.52–0.70) 0.60 (0.55–0.66)
*See Table 2 for risk scores acronyms; CI, confidence interval.
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the four bleeding risk score schemes (Fig. 2,
Panel a). Compared to warfarin, incidence rates
were found to be higher for patients assigned to
dabigatran 150 mg BID according to the increasing
score for all the schemes (p for interac-
tion = 0.0122, P < 0.0001, P < 0.0001 and
P < 0.0001, respectively, for HAS-BLED, ORBIT,
ATRIA and HEMORR2HAGES). Similar results were
reported for life-threatening bleeding (Fig. 2,
Panel b).
In patients assigned to dabigatran 110 mg BID,
higher incidence rates were evident compared to
warfarin based on increasing ORBIT and ATRIA
scores (p for interaction = 0.0051 and P = 0.0047,
respectively) (Fig. 2, Panel a). No significant inter-
actions were found for life-threatening bleeding for
dabigatran 110 mg compared to warfarin (Fig. 2,
Panel b) or intracranial bleeding for both dabiga-
tran 110 mg and 150 mg (Fig. 2, Panel c).
The interaction analyses demonstrated that the
ORBIT, ATRIA and HEMORR2HAGES scores had a
significant interaction with treatment on major
bleeding when comparing patients assigned to
dabigatran 150 mg with those randomized to
Table 4 Discriminative difference compared to HAS-BLED according outcomes*
Difference in C-index (95% CI) vs. HAS-BLED
Major Bleeding Life-Threatening Bleeding Intracranial Bleeding
ORBIT 0.050 (0.036, 0.063) 0.053 (0.009, 0.092) 0.048 (0.026, 0.067)
ATRIA 0.021 (0.005, 0.036) 0.020 (0.032, 0.072) 0.018 (0.008,0.042)
HEMORR2HAGES 0.006 (0.010, 0.020) 0.030 (0.012, 0.076) 0.007 (0.015, 0.029)
*See Table 2 for risk scores acronyms; Bold indicates statistically significant results. CI, confidence interval.
Fig. 1 Bleeding risk scores
calibration between derivation
cohorts and RE-LY cohort event
rates.
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receive warfarin (P = 0.0019, P < 0.0001 and
P < 0.0001, respectively) (Fig. 3, Upper Panel).
Conversely, the HAS-BLED score showed a non-
significant trend for interaction (P = 0.0607)
(Fig. 3, Upper Panel). Only the ATRIA score showed
a significant treatment interaction in patients ran-
domized to dabigatran 110 mg compared to those
assigned to warfarin (P = 0.0097) (Fig. 3, Lower
Panel).
Similarly, ORBIT, ATRIA and HEMORR2HAGES
high-risk categories were found to be associated
with life-threatening bleeding occurrence in
patients assigned to dabigatran 150 mg
(P = 0.0266, P = 0.0021 and P = 0.0073). HAS-
BLED showed a trend in association, despite not
reaching statistical significance (P = 0.0574)
(Table S3). No significant treatment interaction for
life-threatening bleeding was found when compar-
ing dabigatran 110 mg and warfarin according the
four bleeding scores. No significant interaction was
detected for the three randomized treatments
groups across the four scores for the intracranial
bleeding occurrence (Table S3).
Sensitivity analysis
A sensitivity analysis was conducted for HAS-
BLED using an alternative definition for labile
INR (Tables S4 and S5), according the INR value
at randomization (see Supplementary Methods). In
this sensitivity analysis, a significant treatment
interaction for the HAS-BLED score and major
bleeding occurrence was found, with HAS-BLED
high-risk category patients assigned to receive
dabigatran 150 mg, with a significant higher risk
of major bleeding occurrence compared to warfarin
patients (P = 0.0050) (Table S4, Right Column).
Discussion
In this post hoc analysis of the RE-LY cohort, we
found that the HAS-BLED, ORBIT, ATRIA and
HEMORR2HAGES bleeding scores had a signifi-
cant, albeit modest, discriminative capacity in
predicting major and life-threatening bleeding
occurrences. All the bleeding risk scores identified
groups with different risks of major and life-
threatening bleeding outcomes, independently of
treatment with dabigatran or warfarin. Amongst
them, the ORBIT score demonstrated the best
discriminative ability and the best calibration.
The ORBIT, ATRIA and HEMORR2HAGES scores
showed significant treatment interactions, com-
paring dabigatran 150 mg BID and warfarin
according to the predicted bleeding risk at base-
line, for the occurrence of major and life-threaten-
ing bleeding events. The HAS-BLED score showed
Fig. 2 Major bleeding incidence rates according bleeding risk scores and randomized treatment: Panel (a) Major Bleeding;
Panel (b) Life-Threatening Bleeding; Panel (c) Intracranial Bleeding; CI, confidence interval; DE110, dabigatran etexilate
110 mg; DE150, dabigatran etexilate 150 mg; W, warfarin.
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a significant treatment interaction only when com-
puted using the alternative ‘Labile INR’ criterion,
related to the current INR at randomization.
Occurrence of major bleeding events is the most
feared complication for physicians prescribing
OAC [20] and physicians may often overestimate
patients’ bleeding risk, leading to OAC under-
prescription [21] and under-dosing [22]. Data from
a large observational trial in USA, the ‘Outcomes
Registry for Better Informed Treatment of Atrial
Fibrillation’ study, showed that the high risk of
bleeding, as well as the previous history of bleed-
ing, were amongst the most prevalent reasons for
not prescribing OAC [23]. Similarly, data from the
same cohort showed that the high risk of bleeding
was one of the main reasons leading to OAC
discontinuation [24]. Indeed, the concern about
major bleeding seems to disproportionally out-
weigh the risk of stroke amongst some prescribing
physicians [25].
Nonetheless, high risk of bleeding alone should not
bea sufficient reason towithholdOAC treatment. All
Fig. 3 Forest plots for
treatment interactions in major
bleeding occurrence according
bleeding risk scores categories:
CI, confidence interval; DE110,
dabigatran etexilate 110 mg;
DE150, dabigatran etexilate
150 mg, HR, hazard ratio.
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major current guidelines strongly emphasize that all
patients should be evaluated for bleeding risk at
baseline [1–3, 7, 8] and recommend that modifiable
and potentially modifiable bleeding risk factors are
addressed to minimize the risk of bleeding [1]. It is
proposed that patients identified as at high bleeding
risk are monitored more closely. Bleeding risk
should therefore not be considered as definite, but
rather as a continuum, and bleeding risk assess-
ment should routinelybe repeatedat follow-upvisits
and managed appropriately. In this setting, it is
therefore fundamental to use well-calibrated and
validated bleeding risk scores. Another important
issue concerning clinical risk scores is the ease of
use, which may influence the uptake and general-
izability of a score. However, the growing use of
digital calculators and electronic medical charts in
current practicewill likely increase and facilitate the
implementation of more precise risk models and
integrated decision support tools.
Bleeding risk prediction scores are considered by
international guidelines as useful tools to identify
those patients with a prevalent bleeding risk [1, 3,
7]. The performance of HAS-BLED, ATRIA and
HEMORR2HAGES scores has been evaluated and
validated in several previous studies [10, 26–30].
Several comparisons have been performed between
the bleeding risk scores amongst AF patients
treated with vitamin K antagonist, in several
different scenarios, both from real-life cohorts
[31, 32] and post hoc or prospective analyses of
randomized controlled trials [14, 33–35] and have
demonstrated overall modest predictive capacity
for all the scores [31–35], with several of the
previous analyses indicating that the HAS-BLED
score performs better in those patients treated with
vitamin K antagonist [31, 33–35].
To date, there are limited data on the use of
bleeding risk scores in patients treated with
NOACs. The present analyses demonstrate that
all the bleeding risk scores can separate groups
with different risks of major bleeding and life-
threatening bleeding in a large cohort of patients
treated with either warfarin or a NOAC, namely
dabigatran in the present study. The ORBIT score
was validated in the ‘Rivaroxaban Once Daily Oral
Direct Factor Xa Inhibition Compared with Vitamin
K Antagonism for Prevention of Stroke and Embo-
lism Trial in Atrial Fibrillation’ study and demon-
strated slightly better discriminative capacity than
the HAS-BLED and ATRIA bleeding scores (c-
indices: 0.67, 0.64, 0.66, respectively) [10].
Furthermore, the ORBIT score was also shown to
outperform the HAS-BLED score in another large
cohort of patients treated with apixaban, in a
subgroup analysis derived from the ‘Apixaban for
Reduction in Stroke and Other Thromboembolic
Events in Atrial Fibrillation’ study [13]. In the
current RE-LY cohort, the ORBIT score showed the
best predictive ability and calibration. Together
with the previous evidence [10, 13], our data seem
to suggest that the ORBIT score has superior
discrimination and calibration properties than
HAS-BLED when applied to mixed cohorts of
patients, treated with both warfarin and NOACs.
The ORBIT, ATRIA, HEMORR2HAGES scores and to
some extent the HAS-BLED score, managed to iden-
tify a group of high-risk patients that, when treated
with dabigatran 150 mg were more likely to experi-
ence a major bleed. Conversely, the same high-risk
patients had a lower bleeding riskwhen treatedwith
dabigatran 110 mg. This clearly illustrates how
dabigatran can be a safe alternative for AF patients
even at a high risk of bleeding using amore ‘person-
alized treatment’ based on one of these bleeding
scores when considering themost suitable dose.
Limitations
The main limitation of the current analysis is its
retrospective nature, and therefore, the original
study design was not specifically powered to detect
differences in the subgroups under consideration.
In addition, this analysis was performed on a cohort
of AF patients from a randomized controlled trial;
thus, our results may not be completely generaliz-
able to the overall AF population. Also, additional
cardiovascular biomarkers were not available in all
patients, and therefore, the recently developedABC-
bleeding risk score [13] was not included in the
present analyses. Finally, despite reporting overall
significant predictive properties, all the scores
demonstrated a rather modest prediction ability.
Conclusions
All the bleeding risk scores identified patient groups
with different risks of major bleeding and life-
threatening bleeding with modest and variable dis-
criminative ability. The ORBIT score demonstrated
superior discrimination and calibration in this large
randomized clinical trial of AF patients. All the
bleeding risk scores demonstrated, to a variable
extent, a significant interaction with the bleeding
risk associated with dabigatran or warfarin.
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